Adoptive T cell transfer (ACT) using tumor-specific CD8+ T-cells are selected with specific tumor-associated antigens, expanded and activated with cytokines including interleukin (IL)-2, -7 and -15, then transfused back to the patient [1, 2]. The gene discussed is IL2; the disease is neoplasm.